Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close change Change (%) Open High Low

VirBiotechnology news

Latest news

Show more
Frances Wang 2025 May 13, 16:00

XRP News Today: XRP Rises on Increased Bank Demand in the US

Cryptocurrencies
Tommy Yap 2025 May 13, 16:00

Morning Note: Tencent's Report in Focus; Gold Affected by Trade Optimism; Oil Stable

Morning Note China Commodities
Frances Wang 2025 May 12, 16:00

ADA crypto price forecast: What factors influence the price of Cardano?

Cryptocurrencies
Tommy Yap 2025 May 12, 16:00

Morning Note: Tariff Rollback Sparks Stock Rally; US CPI Watch; Bailey's Speech

Morning Note Equities
Tommy Yap 2025 May 12, 04:00

Morning Note: US Surplus Expected; Denmark Inflation; UK Retail Sales Forecast

Morning Note EUR
Frances Wang 2025 May 11, 16:00

How the US-China Trade War Influenced Global Commodity Markets?

Commodities
Tommy Yap 2025 May 09, 21:00

Week Ahead: U.S. Inflation Data in Spotlight

Forex Indices
Frances Wang 2025 May 08, 16:00

What Is Happening to the Bond Market: Bond Market Outlook 2025

Bonds

Info

Spread

0.03

Spread (%)

0.6711 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Market open

Wednesday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

731739200

Shares Outstanding

138064000

Earnings Date (Next)

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

EPS

-4.23

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Markets.com Bonus Trading

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Markets.com Bonus Trading
Trustpilot